Dr. Peter Voorhees Shares ‘Impressive Results’ From CARTITUDE-1 Trial in Myeloma

Peter Voorhees, MD, of the Atrium Health Levine Cancer Institute, shared 5-year survival and safety data from the CARTITUDE-1 trial of ciltacabtagene autoleucel (cilta-cel) for relapsed or refractory multiple myeloma presented at the 2025 American Society of Clinical Oncology (ASCO) Meeting.

“Just with a single cilta-cel infusion, we’re showing that at 5 years and beyond, 33% of patients are alive and disease free, which is unprecedented in this patient population,” Dr. Voorhees explained.

He also described the significance of measurable residual disease (MRD) testing in this patient population and how it correlated with progression-free survival.

“At the 5-year mark, one of the institutions that contributed the largest number of patients who are disease-free did serial MRD testing on an annual basis,” Dr. Voorhees explained. “Of those 12 patients from that institution, all of them were MRD negative at 10^–6 level of sensitivity at 5 years and beyond…This is the most impressive results that we’ve seen in this group of patients.”